MTT Assay for Chemosensitivity in Acute Myeloid Leukaemia
Author Information
Author(s): J.M. Sargent, C.G. Taylor
Primary Institution: Department of Haematology, Pembury Hospital, Pembury, UK
Hypothesis
Can the MTT assay effectively predict drug sensitivity in patients with acute myeloid leukaemia?
Conclusion
The MTT assay is a reliable method for assessing drug sensitivity in acute myeloid leukaemia patients.
Supporting Evidence
- The MTT assay showed a linear relationship between the number of leukaemic cells and the optical density of formazan produced.
- The assay demonstrated variation in drug sensitivity between patients.
- The technique was reproducible with no significant difference in response between blast cells from bone marrow and peripheral blood.
- Preliminary results indicated a correlation between in vitro and in vivo data.
Takeaway
Doctors can use a simple test to see how well cancer drugs work on patients' leukemia cells, helping them choose the best treatment.
Methodology
The MTT assay was used to test the sensitivity of blast cells from bone marrow to various cytotoxic drugs after 48 hours of exposure.
Limitations
The study had a small sample size and included patients with varying stages of disease.
Participant Demographics
18 patients with de novo AML and 5 with chronic myeloid leukaemia in blast crisis.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website